FARAN remains true to its vision and values, implementing its commitment to the Greek patient and the health system, offering renowned therapeutic proposals of high quality and therapeutic value for the treatment of haematological malignancies. FARAN’s therapeutic portfolio consists of original, biosimilar as well as generic products and covers a wide range of treatments against Leukaemia, Multiple Myeloma and Myelodysplastic syndromes.